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MULTI-INSTITUTIONAL COLLABORATIVE STUDY ON LONG-
TERM SURVIVORS OF CHILDHOOD CANCER
L. Aung a,*, S.M. Sabai b, Y.H. Chan c. a Division of Pediatric
Hematology-Oncology, KK Womens and Childrens Hospital,
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Background: Worldwide, survival rates among childhood can-
cer patients are increasing; thus, assessing the risk of late effects
and complications is important.
Methods: The Singapore Childhood Cancer Registry (1981–2005)
included 704 patients from KK Womens and Childrens Hospital
and 626 from the National University Hospital (NUH). The Singa-
pore Childhood Cancer Survivor Study (SIN-CCSS) consisted of all
individuals who survived at least 2 or more years after treatment
for cancer diagnosed during childhood or adolescence.
Findings: A total of 1043 (72.4%) of 1440 patients are alive, of
which 839 (80.4%) are long-term survivors. 58.6% (n = 492) survi-
vors had haematological malignancies, whereas 41.4% (n = 347)
were diagnosed with various solid tumours. To date, 79 survivors
have enrolled in the study at NUH. Mean age was 14.9 years (range
4.9–31.8); 55.7% were male, 11.4% were an only child, 58.2% were
Singaporean, and 74.4% were Chinese. 27.8% continued to see the
doctor once or twice per year and 12.7% of these visits were
related to previous illness. Preliminary analysis shows that
21.8% of participants reported anxiety. Endocrine adverse effects
were most common (40.4%), followed by respiratory complaints
(37.9%).
Interpretation: At least 58% of those diagnosed with childhood
cancer are long-term survivors. This is the first study of its kind
in Singapore, looking at long-term survivors of childhood cancer
with a multicultural and multiethnic approach. In the future, we
plan to focus on prevention of late effects, aetiological (genetic
and environmental) and outcomes research, and survivor
education.
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Background: Human hepatocellular carcinomas (HCCs) are the
fifth most common malignant tumours worldwide, and the third
leading cause of cancer-related death. In view of the high postop-
erative recurrence rate, identification of potential biomarkers
should be considered; these can be a diagnostic marker, prognos-
tic marker, or target for cancer therapy. MicroRNAs (miRNAs)
have been proposed to contribute to oncogenesis because they
can function either as tumour suppressors or oncogenes.
Methods To search the useful index marker to predict postoper-
ative recurrence rate of patients with HCC, adjacent noncancer-
ous liver tissues from HCC patients with good prognosis (n = 6)
and poor prognosis (n = 6) were collected. 270 miRNA expression
profiles were analysed using a highly sensitive stem-loop reverse
transcriptase (RT)-PCR method.
Findings: 20 miRNA candidates were found that were associa-
tion with good and poor prognosis. Further screening of 216
adjacent non-cancerous liver tissues identified six miRNAs signif-
icantly correlated with disease-free survival (p < 0.021). Cox pro-
portional-hazards analysis revealed that high expression of
miR-A6 and miR-A18 were the most significant markers associ-
ated with poor disease-free survival (p = 0.013, hazard ratio [HR]
1.633 [95% CI 1.108–2.408]; p = 0.001, HR 1.929 [1.298–2.867],
respectively). High expression of miR-A3 and miR-A19 were the
most significant markers related to better disease-free survival
(p = 0.012, HR 0.431, 95% CI [0.224–0.830]; p = 0.001, HR 0.529,
[0.357–0.783], respectively). Additionally, in J7 cells transduced
with anti-miR-A6 lentivirus, cell-growth suppression was
observed and cell-cycle related molecules, including CDK2,
CDK4, cyclin E, and cyclin D1, were underexpressed.
Interpretation: miRNAs associated with good and bad prognosis
can serve as biomarkers for HCC.
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P31 EXPRESSION OF NEUROENDOCRINE MARKERS IN NON-
SMALL-CELL LUNG CARCINOMAS AND ASSOCIATION WITH
POST-OPERATIVE SURVIVAL
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Introduction: Neuroendocrine differentiation has been sug-
gested as a marker of poor prognosis in 10–30% of non-small-cell
lung carcinomas (NSCLCs). We studied immunohistochemical
expression of the neuroendocrine markers chromogranin A
(CgA), synaptophysin (SYN), histidine decarboxylase (HDC), and
neuron-specific enolase (NSE) in various subtypes of NSCLCs,
and noted whether there was any association with post-operative
survival.
Methods: 225 patients (mean age 45 years) diagnosed with
NSCLCs were surgically treated at Gulab Devi Chest Hospital,
Lahore, Pakistan from January, 2004, to January, 2006. Relevant
clinical and laboratory data including age, sex, tumour location,
and type of surgical procedure were recorded in separate profor-
mas. After haematoxylin and eosin staining, paraffin-embedded
tissue blocks of tumour specimens were stained immunohisto-
chemically with monoclonal anti-CgA, anti-SYN, anti-HDC, and
anti-NSE antibodies. A total of 153 patients were followed up for
4.5 years, and the shortest follow-up time was 13 months. COX
proportional-hazard multivariate analysis was applied to observe
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